Objective
In the vaccine industry, downstream processing is of extreme importance. Prophylactic vaccines aim at protecting healthy people, so any contaminant has to be discarded with the most drastic measures. Such « negative » approach comes at the expense of the recovery of product : yields are poor, thereby inducing a high product cost. Processes are also complex, since they rely on multiple eliminations rather than on recovery of the unique product of interest. Technically, this is mostly due to the lack of specific capture systems that would allow direct, « positive » separation of the vaccine from its environment.Vaccines know no borders. For developing countries, the pressure on costs is even more acute, and local production is a way to try to reach the 1$ per dose target. In this context, water sustainability is a major issue, as it is a most sensitive ingredient in bioproduction.
DiViNe will tackle theses cost and environmental issues with technological answers. The partners will combine two major Nano/biotechnology innovations to develop an integrated purification platform amenable to the different natures of vaccines : glycoconjugates, protein antigens and enveloped viruses. They will implement Nanofitins (novel affinity capture ligands) and Aquaporin-based membranes (energy-saving nano-biomimetics used in the cleantech industry), for a « positive » purification approach. High yields are expected (data from antibody purification with Nanofitins), at affordable cost of goods and with a sustainable approach of water recycling.
Novartis Vaccines brings to the Consortium a broad range of targets, and identical strategies can be applied for biopharmaceuticals in general. The development custom affinity capture processes as a sustainable platform is therefore economically relevant, in a very large market. Beyond the technical partnership, the project is a first run for the partners to structure the platform as a commercial offer for downstream processing of biologics.
Fields of science
- medical and health scienceshealth sciencesinfectious diseasesRNA viruses
- engineering and technologyenvironmental engineeringwaste managementwaste treatment processesrecycling
- natural sciencesbiological sciencesmicrobiologyvirology
- natural sciencesbiological sciencesbiochemistrybiomoleculesproteins
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccines
Programme(s)
Funding Scheme
IA - Innovation actionCoordinator
2781-901 Oeiras
Portugal
See on map
Participants (6)
44300 Nantes
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
2800 Kobenhavn
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
64293 Darmstadt
See on map
2781 901 Oeiras
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
53100 Siena
See on map
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
1330 Rixensart
See on map